Efgartigimod Alfa

• A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem) Pending
  2023-510216-39-00 Phase II 1 country Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
• Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC Pending
  2025-521130-28-00 Phase III 4 countries Janssen Cilag International
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 Phase II/III 2 countries Medizinische Hochschule Hannover
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting
  2025-522492-28-00 Phase II 7 countries Argenx
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th… Recruiting
  2025-521055-23-00 Phase II/III 8 countries Argenx
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 Phase III 14 countries Argenx
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD… Recruiting
  2023-507379-23-00 Phase II/III 9 countries Argenx
• A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting
  2024-514539-67-00 Phase II 16 countries Argenx
• Efficacy and tolerability of efgartigimod as early treatment in patients with generalized myasthenia gravis. Recruiting
  2024-516015-24-00 Phase IV 1 country Bellvitge University Hospital; Fundacio Institut D'Investigacio Biomedica De Bel…
• A study of efgartigimod PH20 SC in children between 2 and less than 18 years of age with generalized myasthenia gravis Recruiting
  2023-506159-12-00 Phase II/III 8 countries Argenx
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasth… Recruiting
  2024-513854-31-00 Phase II/III 7 countries Argenx
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel… Recruiting
  2023-507885-21-00 Phase II 11 countries Argenx
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended
  2024-516609-22-00 Phase III 18 countries Argenx
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended
  2024-514133-38-00 Phase III 15 countries Argenx
• A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re… Ended
  2023-508180-72-00 Phase II 6 countries Argenx
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative… Ended
  2024-511796-15-00 Phase III 15 countries Argenx
• A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended
  2024-512785-33-00 Phase II/III 19 countries Argenx
• Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni… Ended
  2024-513147-90-00 Phase III 6 countries Argenx
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 Phase III 10 countries Argenx
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 Phase III 10 countries Argenx
• Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended
  2023-503915-14-00 Phase II 3 countries Argenx
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 Phase II/III 14 countries Argenx
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult… Ended
  2024-515832-59-00 Phase III 10 countries Argenx

Showing 1–24 of 26 trials